Division of Digestive and Liver Diseases, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA.
Department of Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Gut. 2021 Feb;70(2):330-341. doi: 10.1136/gutjnl-2019-319912. Epub 2020 May 10.
Long-standing chronic pancreatitis is an established risk factor for pancreatic ductal adenocarcinoma (PDAC). Interleukin-1β (IL-1β) has been associated in PDAC with shorter survival. We employed murine models to investigate the mechanisms by which IL-1β and chronic pancreatitis might contribute to PDAC progression.
We crossed LSL-;-Cre (KC) mice with transgenic mice overexpressing IL-1β to generate KC-IL1β mice, and followed them longitudinally. We used pancreatic 3D in vitro culture to assess acinar-to-ductal metaplasia formation. Immune cells were analysed by flow cytometry and immunohistochemical staining. B lymphocytes were adoptively transferred or depleted in Kras-mutant mice. B-cell infiltration was analysed in human PDAC samples.
KC-IL1β mice developed PDAC with liver metastases. IL-1β treatment increased Kras pancreatic spheroid formation. CXCL13 expression and B lymphocyte infiltration were increased in KC-IL1β pancreata. Adoptive transfer of B lymphocytes from KC-IL1β mice promoted tumour formation, while depletion of B cells prevented tumour progression in KC-IL1β mice. B cells isolated from KC-IL1β mice had much higher expression of PD-L1, more regulatory B cells, impaired CD8 T cell activity and promoted tumorigenesis. IL-35 was increased in the KC-IL1β pancreata, and depletion of IL-35 decreased the number of PD-L1 B cells. Finally, in human PDAC samples, patients with PDAC with higher B-cell infiltration within tumours showed significantly shorter survival.
We show here that IL-1β promotes tumorigenesis in part by inducing an expansion of immune-suppressive B cells. These findings point to the growing significance of B suppressor cells in pancreatic tumorigenesis.
长期慢性胰腺炎是胰腺导管腺癌(PDAC)的既定危险因素。白细胞介素-1β(IL-1β)与 PDAC 患者的生存时间缩短有关。我们使用小鼠模型研究了 IL-1β 和慢性胰腺炎如何促进 PDAC 进展的机制。
我们将 LSL-;-Cre(KC)小鼠与过表达 IL-1β的转基因小鼠杂交,生成 KC-IL1β 小鼠,并对其进行纵向跟踪。我们使用胰腺 3D 体外培养来评估腺泡到导管的化生形成。通过流式细胞术和免疫组织化学染色分析免疫细胞。在 Kras 突变小鼠中过继转移或耗尽 B 淋巴细胞。分析人类 PDAC 样本中的 B 细胞浸润。
KC-IL1β 小鼠发展为 PDAC 并伴有肝转移。IL-1β 治疗增加了 Kras 胰腺球体的形成。KC-IL1β 胰腺中 CXCL13 表达和 B 淋巴细胞浸润增加。从 KC-IL1β 小鼠过继转移 B 淋巴细胞促进肿瘤形成,而 KC-IL1β 小鼠中 B 细胞的耗竭则阻止了肿瘤的进展。从 KC-IL1β 小鼠分离的 B 细胞具有更高的 PD-L1 表达、更多的调节性 B 细胞、受损的 CD8 T 细胞活性和促进肿瘤发生的能力。KC-IL1β 胰腺中 IL-35 增加,IL-35 的耗竭减少了 PD-L1 B 细胞的数量。最后,在人类 PDAC 样本中,肿瘤内 B 细胞浸润较高的 PDAC 患者的生存时间明显缩短。
我们在这里表明,IL-1β 通过诱导免疫抑制性 B 细胞的扩增促进肿瘤发生。这些发现表明 B 抑制细胞在胰腺肿瘤发生中的重要性日益增加。